Compare Prudential PLC (PUK) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs Tango Therapeutics Inc. — how do they compare? Prudential PLC trades at $23.69 (market cap $29.00B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Prudential PLC is far larger — about 7.7× Tango Therapeutics Inc.'s market cap, and Prudential PLC pays a 2.33% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential PLC for 119 Days and Tango Therapeutics Inc. for 0 Days on average.
| PUK | TNGX | |
|---|---|---|
Market Cap | $29.00B | $3.75B |
Volume | 1,133,946 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $33.61 | $32.90 |
52-Week Low | $23.54 | $7.50 |
Typical Hold Time | 119 Days | 0 Days |
Enterprise Value | $28.54B | $2.77B |
Dividend Yield | 2.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Public Limited Company (PUK) trades at $23.81, down 0.25% on the day, with mixed technical signals showing bearish moving averages but oversold RSI readings. The company demonstrates strong fundamentals with $27.39B revenue in 2025, 12.27% net income margin, and attractive valuation metrics including an 8.38 P/E ratio. Recent earnings show two beats and two misses in the last four quarters, while analyst sentiment remains moderately positive with 50% buy ratings.
PUK presents a compelling value opportunity with strong profitability and growth in Asian markets, though near-term technical weakness and emerging market exit execution risks warrant caution. The stock's current valuation discount to peers and consistent dividend payments provide downside protection, while strategic refocusing on core markets could drive long-term shareholder value.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
